OTCMKTS:RDSMY - Koninklijke DSM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$47.26
▲ +0.45 (0.96%)

This chart shows the closing price for RDSMY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Koninklijke DSM Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RDSMY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RDSMY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 8 analysts offering 12 month price targets for Koninklijke DSM in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $47.26.

This chart shows the closing price for RDSMY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 contributing investment analysts is to buy stock in Koninklijke DSM. This rating has held steady since April 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
1/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
3/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 2 sell ratings
6/29/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings
9/27/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 2 sell ratings
3/26/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/18/2021BarclaysUpgradeOverweight
4/19/2021JPMorgan Chase & Co.Initiated CoverageOverweight
2/17/2021BarclaysReiterated RatingOverweight
2/17/2021UBS GroupReiterated RatingBuy
2/17/2021Credit Suisse GroupReiterated RatingOutperform
1/20/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform
1/12/2021Sanford C. BernsteinDowngradeMarket Perform ➝ Underperform
11/10/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
11/4/2020Credit Suisse GroupReiterated RatingNeutral
10/14/2020Morgan StanleyReiterated RatingEqual Weight
10/1/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
7/24/2020Main First BankUpgradeHold ➝ Buy
7/15/2020Credit Suisse GroupReiterated RatingNeutral
7/8/2020UBS GroupReiterated RatingBuy
7/6/2020Credit Suisse GroupReiterated RatingNeutral
6/29/2020JPMorgan Chase & Co.Reiterated RatingOverweight
5/13/2020JPMorgan Chase & Co.Reiterated RatingOverweight
4/29/2020ING GroupDowngradeHold ➝ Sell
4/15/2020JPMorgan Chase & Co.Reiterated RatingOverweight
3/30/2020Morgan StanleyReiterated RatingEqual Weight
3/24/2020JPMorgan Chase & Co.Reiterated RatingOverweight
11/27/2019Sanford C. BernsteinDowngradeMarket Perform ➝ Underperform
8/5/2019ABN AmroDowngradeBuy ➝ Hold
7/5/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
2/1/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy
11/29/2018MacquarieInitiated CoverageOutperform ➝ Outperform
12/1/2017Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
3/28/2017Liberum CapitalUpgradeHold ➝ Buy
3/9/2017JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
1/6/2017BarclaysUpgradeEqual Weight ➝ Overweight
10/26/2016JPMorgan Chase & Co.DowngradeOverweight ➝ Underweight
(Data available from 6/24/2016 forward)
Koninklijke DSM logo
Koninklijke DSM N.V., a science-based company, engages in nutrition, health, and sustainable living businesses in the Netherlands, rest of Europe, North America, Latin America, China, India, Japan, rest of Asia, and internationally. It operates through Nutrition, Materials, and Innovation Center segments. The Nutrition segment offers animal nutrition and health products, including vitamins, enzymes, eubiotics, carotenoids, lipids, and minerals; human nutrition and health products comprising carotenoids, digestive enzymes, nutritional lipids, nutraceuticals, probiotic and prebiotics, human milk oligosaccharides, and vitamins, as well as premix, market-ready solutions, and personalized nutrition; and skin and sun care, hair care, and aroma ingredients. It also provides vitamin and lipid active pharmaceutical ingredients; omega-3 fatty acids; specialty food enzymes, cultures, probiotics, bio-preservation, sugar reduction, and savory taste solutions; and specialty hydrocolloid solutions. The Materials segment provides thermoplastics used in automotive, electrical and electronics, building and construction, medical, food packaging, and consumer goods; and Dyneema, a fiber solution for use in ropes and lines, and outdoor and sports applications. The Innovation Center segment offers biomedical materials, and medical device and material manufacturing technologies in the areas of cardiovascular, dental, diabetes management, gynecology, neurology, ophthalmology, orthopedic, plastic and reconstructive surgery, soft tissue, and wound management. It also provides yeast and enzymes for the conversion of starch, corn fiber, and biomass. Koninklijke DSM N.V. has a strategic partnership with Mile High Labs, LLC to develop and commercialize science-backed cannabinoid consumer products. The company was founded in 1902 and is headquartered in Heerlen, the Netherlands.
Read More

Today's Range

Now: $47.26
Low: $46.98
High: $47.26

50 Day Range

MA: $45.91
Low: $44.26
High: $47.26

52 Week Range

Now: $47.26
Low: $33.74
High: $47.26

Volume

17,809 shs

Average Volume

34,112 shs

Market Capitalization

$34.30 billion

P/E Ratio

57.63

Dividend Yield

1.67%

Beta

0.79

Frequently Asked Questions

What sell-side analysts currently cover shares of Koninklijke DSM?

The following Wall Street sell-side analysts have issued reports on Koninklijke DSM in the last twelve months: Barclays PLC, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Main First Bank AG, Morgan Stanley, Sanford C. Bernstein, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for RDSMY.

What is the current price target for Koninklijke DSM?

0 Wall Street analysts have set twelve-month price targets for Koninklijke DSM in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Koninklijke DSM in the next year.
View the latest price targets for RDSMY.

What is the current consensus analyst rating for Koninklijke DSM?

Koninklijke DSM currently has 1 sell rating, 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RDSMY will outperform the market and that investors should add to their positions of Koninklijke DSM.
View the latest ratings for RDSMY.

What other companies compete with Koninklijke DSM?

How do I contact Koninklijke DSM's investor relations team?

Koninklijke DSM's physical mailing address is Het Overloon 1, Heerlrn P7, 6411 TE. The basic materials company's listed phone number is 31-45-578-2864. The official website for Koninklijke DSM is www.dsm.com.